Dr. Kutikov on Tumor Pathology in Renal Cell Carcinoma

Video

Alexander Kutikov, MD, FACS, attending surgeon, urologic oncology, associate professor, urologic oncology, Fox Chase Cancer Center, discusses the understanding of tumor pathology in renal cell carcinoma.

Alexander Kutikov, MD, FACS, attending surgeon, urologic oncology, associate professor, urologic oncology, Fox Chase Cancer Center, discusses the understanding of tumor pathology in renal cell carcinoma.

Treatment of renal cell carcinoma has been boiled down to calibrating imbalanced risk, Kutikov explains. When consulting a patient who presents a renal mass, it is questionable whether to treat it or to use active surveillance. However, there needs to be a greater understanding of active surveillance and associated risks of that, he adds.

The urologic community is aiming to better understand tumor pathology in renal cell carcinoma, prior to tumor resection, Kutikov says. An example of this would be to better utilize renal biopsies.

<<<

View more from the 2015 AUA Annual Meeting

Related Videos
Samer A. Srour, MB ChB, MS
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Samer A. Srour, MB ChB, MS
Samer A. Srour, MB ChB, MS
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
A panel of 5 experts on renal cell carcinoma
Chandler H. Park, MD, an expert on renal cell carcinoma
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Eric S. Christenson, MD
Benjamin Garmezy, MD